Skin toxicities are the most common side effects associated with the epidermal growth factor
receptor inhibitor erlotinib, occurring in most patients receiving the drug. Clinical trials …

Advances in the knowledge of tumor biology and mechanisms of oncogenesis has granted
the singling out of several molecular targets for non-small cell lung cancer (NSCLC) …

Rash has been reported in up to 76% of patients with lung cancer who have received the
epidermal growth factor receptor inhibitor (EGFRI) erlotinib. It has also been observed in …

Purpose Erlotinib is an epidermal growth factor receptor inhibitor approved for patients with
advanced non–small-cell lung cancer (NSCLC) whose epidermal growth factor receptor …

The human epidermal growth factor receptor (EGFR) signaling is overexpressed in many
solid malignancies, making it an appealing target for biologic agents. A number of agents …

Background: To evaluate the anticancer activity of erlotinib in patients with previously
treated, advanced non-small cell lung cancer (NSCLC) whose dose is increased to that …

Objectives An association between skin toxicity and outcome has been reported for NSCLC
patients treated with erlotinib. Several explanations have been suggested, including …

Rash and other cutaneous adverse events are class-effect toxicities seen with therapeutic
agents such as the small-molecule tyrosine kinase inhibitors erlotinib and gefitinib and …

Epidermal growth factor receptor (EGFR) inhibitors are associated with unique and dramatic
dermatologic side effects. Skin rash is the dose-limiting factor for all EGFR inhibitors and is …

Background The development of a rash has been retrospectively associated with increased
response and improved survival when treated with erlotinib at the standard dose of 150 mg …